Akari Therapeutics, Plc announced the appointment of Michael Grissinger and Dr. Peter Feldschreiber to the company’s Board of Directors with immediate effect. Mr. Grissinger spent 22 years at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He has led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger brings to Akari Therapeutics extensive experience in business and corporate development, finance, marketing and strategic planning in the pharmaceutical industry. Dr. Feldschreiber is dually qualified as a physician and barrister with extensive experience both in the pharmaceutical industry and healthcare law. He has over 20 years’ experience in the pharmaceutical industry including 10 years as European Medical Director at Proctor and Gamble Limited, and he has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Commission on Human Medicines, as well as the Committee on Safety of Devices, Medicines, and Healthcare Products Regulatory Agency, part of the U.K. government’s Department of Health.